China, America and pay inject drama into AstraZeneca’s AGM

This year’s annual general meeting at AstraZeneca, Britain’s largest company, is not just about the boss’s bonus, but also about other pressing issues. The company, valued at about £170bn, is facing investigations in China over import and data breaches, as well as controversy over abandoning a £450m expansion of its vaccine site in Speke. These challenges have overshadowed the meeting, which is also marked by protests over CEO Pascal Soriot’s high pay.

Full Article